And Pfizer plans to relocate most of its 530 employees from its operations in the Alewife section of Cambridge closer to where about 400 of the pharma giant's employees are working in Kendall Square, The Boston Globe reported.
Today's Telegraph gives AstraZeneca a rousing hurrah today in a lengthy piece, noting that its plans to build a new $500 million facility in Cambridge, U.K., has the potential to fast-track the area's emergence as a major global biotech hub.
J&J is about to make a big entrance in the Boston/Cambridge hub. The Boston Business Journal reports today that the pharma giant has taken a lease on new digs in Kendall Square for one of its four global innovation centers--putting it right in the heart of one of the busiest biotech regions in the world.
Like pioneers rushing for gold, biotech and pharma outfits have swept into Cambridge, MA, and dismissed the hefty property costs in search of talent and technology that could lead to lucrative new drugs.
Plans call for the Massachusetts Accelerator for Biomanufacturing to attract a host of startups and companies that will hopefully put the small city on the biotech map.
Damage caused by multiple sclerosis could possibly be reversed by activating stem cells that can repair injury, a study has shown. Researchers from the Universities of Cambridge and Edinburgh have
After watching the controversy surrounding a high-security biolab in Boston, officials in Cambridge are preparing new rules that would bar development of such labs in their town. Report
Biotech giant Biogen Idec is joining the migration of Cambridge drug developers to the burbs. The company has inked a lease for 350,000 square feet of space for its new corporate headquarters in
Some much-needed good news for the UK: MedImmune has opened a new biologics R&D facility in Cambridge that it says will boost the